For years, Americans have been bearing the financial brunt of global drug development. While European nations enjoy subsidized medication under their single-payer systems, U.S. consumers have footed the bill—essentially underwriting Big Pharma’s R&D tab. But President Trump has had enough of that lopsided deal.

With a bold stroke of the pen, Trump has unveiled a sweeping executive order to slash prescription drug prices in the United States.

The order mandates that the Department of Health and Human Services (HHS) bring U.S. drug prices in line with the lowest prices paid by peer nations. That could mean savings of 30% to 80% for Americans. HHS Secretary RFK Jr. now has 30 days to establish price reduction targets—and if pharmaceutical companies fail to make “adequate progress” within six months, HHS will bring down the hammer with Most Favored Nation (MFN) pricing via federal rulemaking.

But the plan doesn’t stop there. The U.S. Trade Representative and Secretary of Commerce are being sent into the ring to challenge foreign practices that inflate American drug costs. Simultaneously, the order opens the door to importing cheaper drugs from countries beyond Canada and empowers the Department of Justice and Federal Trade Commission to crack down on anti-competitive behavior that jacks up prices.

Even more radically, Trump is pushing for programs that let patients buy medications directly from manufacturers—at MFN prices—cutting out the middlemen and breaking the pharmacy benefit manager stranglehold.

Now, don’t start celebrating just yet. If recent history has shown us anything, it’s that the courts love to block Trump’s moves—and there’s a solid chance this effort could get tied up in litigation.

That’s why congressional action is key. Joe Biden had 11 bills signed into law within his first 100 days—helped by Nancy Pelosi’s Democrat-controlled House. This time? Republicans have managed to send only five to Trump’s desk. It’s time for lawmakers to step up and match Trump’s energy.

Democrats have campaigned on lowering drug costs for decades—and done next to nothing about it. Here’s a perfect chance to prove they meant it. Will they finally rise to the occasion? Judging by their track record, don’t hold your breath.

Meanwhile, in another huge win for the Trump administration, the United States and China have agreed to a 90-day pause on retaliatory tariffs.

The deal slashes U.S. tariffs on Chinese goods from 145% to 30% and cuts Chinese tariffs on American products from 125% to just 10%. The Dow responded with a 1,000-point rally. Retailers, tech stocks—you name it—are riding high. With back-to-school shopping and the holiday season on the horizon, this couldn’t come at a better time.

This is classic Trump: leverage, pressure, and bold negotiation. He’s already floated the idea of meeting with President Xi to seal a final deal—on American terms.

Compare that to the Biden years, where weakness was the default strategy. Treasury Secretary Scott Bessentt, during trade talks in Geneva this weekend, let the cat out of the bag—

China ignored Biden because they knew he was a pushover. With Trump, they know better.

And the wins keep rolling in. The last American hostage believed to be alive has returned home. His mother got to speak with him for the first time in 500 days, as Trump’s Middle East envoy Steve Witkoff handed her the phone—

No translation needed. Her emotion says it all. Trump promised to bring Americans home—and he’s delivering.

Add to that the possibility of real peace talks between Ukraine and Russia, calm in Gaza, and a détente between Pakistan and India—and suddenly that Nobel Peace Prize doesn’t seem like such a long shot. He should’ve gotten it for the Abraham Accords, but the Nobel Committee isn’t exactly known for rewarding Trump’s success. Still, he doesn’t do it for the accolades—he does it because it’s the right thing to do.

And what do the Democrats have in their corner? Weak rhetoric, identity politics, and zero fresh ideas. Case in point: Representative Jasmine Crockett recently laid out the party’s 2024 strategy—

Apparently, their master plan is to run a “safe white boy.” They’ve learned nothing. It’s always race or gender—never ideas, merit, or results.

Even liberal comedian Bill Maher is sounding the alarm.

He’s right. Elissa Slotkin’s right. But they’ve hitched their wagon to the wrong party.

If Trump keeps delivering the way he has over the past week—and if Congress actually follows through—Democrats may find themselves politically bankrupt. Because in the end, America isn’t asking for much. Just results. And Trump’s serving them up faster than the left can say “resistance.”